Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Gaucher disease, Parkinson's disease, and related disorders are expensive, have significant side effects, or become ineffective over time, necessitating the need for new therapeutic agents with improved efficacy and reduced adverse effects.
Innovation Solution
Development of crystalline 5,7-dimethyl-N-((1S*,4S)-4-(pentyloxy)cyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide compounds in various forms, including polymorphs A, B, C, and hydrate D, for use in pharmaceutical compositions to treat conditions such as Gaucher disease, Parkinson's disease, and other medical disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat Gaucher disease, then treatment efficacy is achieved, but treatment cost increases
Solution Approach 1:
The patent provides small molecule oral compounds (e.g., milnacipran, vilazodone, levomilnacipran) that are significantly less expensive than enzyme replacement therapy. These compounds act as glucocerebrosidase activators or modulators, providing a cost-effective alternative that maintains treatment efficacy while reducing the financial burden on patients.
Solution Approach 2:
The patent modifies the therapeutic approach by changing the mechanism of action from direct enzyme replacement to enzyme activation/modulation. The compounds alter the enzymatic activity parameters of glucocerebrosidase, achieving therapeutic effects at lower costs compared to providing the enzyme directly through replacement therapy.
2Reliability
If levodopa and dopamine agonists are used to treat Parkinson's disease, then symptom relief is achieved, but side effects increase
Solution Approach 1:
The patent provides alternative therapeutic compounds (e.g., milnacipran, vilazodone, levomilnacipran) that offer symptom relief with fewer and less severe side effects compared to conventional levodopa and dopamine agonists. These compounds provide a safer long-term treatment option with improved tolerability.
Solution Approach 2:
The patent identifies and addresses the harmful side effects of conventional Parkinson's disease treatments by providing alternative compounds that mechanismically avoid these harmful effects while maintaining therapeutic benefit. The new compounds reduce the harm-to-benefit ratio by eliminating severe adverse effects such as hallucinations, insomnia, and dyskinesia.
3Reliability
If conventional treatments are used long-term, then initial efficacy is achieved, but drug effectiveness decreases over time
Solution Approach 1:
The patent provides novel compounds with sustained therapeutic effectiveness that do not develop tolerance or lose efficacy over time like conventional treatments. The compounds (e.g., milnacipran, vilazodone, levomilnacipran) maintain stable pharmacological activity and therapeutic response throughout prolonged treatment periods.
Solution Approach 2:
The patent ensures continuous therapeutic effectiveness by providing compounds that maintain consistent pharmacological activity over time. The mechanism of action of these compounds allows for sustained enzyme modulation or activation without the waning effectiveness that characterizes conventional treatments, ensuring uninterrupted therapeutic benefit.
Data Source
AI summary
The invention provides crystalline 5,7-dimethyl-N-((1S*,4S)-4-(pentyloxy)cyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, compositions containing the crystalline compound, methods for making the crystalline compound, medical kits, and methods for using the crystalline compound and compositions to treat a medical disorder, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient.